CERS Key Statistics, Chart & Performance
The current stock price of CERS is 2.09 USD. In the past month the price increased by 11.76%. In the past year, price increased by 32.28%.
CERS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 20.31 | 16.68B | ||
| SOLV | SOLVENTUM CORP | 14.18 | 14.61B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.25 | 11.97B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 24.64 | 5.43B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.64 | 4.60B | ||
| HAE | HAEMONETICS CORP/MASS | 17.29 | 3.89B | ||
| ICUI | ICU MEDICAL INC | 18.88 | 3.71B | ||
| XRAY | DENTSPLY SIRONA INC | 7.83 | 2.47B | ||
| UFPT | UFP TECHNOLOGIES INC | 28.91 | 1.92B | ||
| NEOG | NEOGEN CORP | 24.6 | 1.60B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.10B | ||
| EMBC | EMBECTA CORP | 4.21 | 731.38M |
Related stock screener links
About CERS
Company Profile
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 281 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Company Info
CERUS CORP
1220 Concord Avenue
Concord CALIFORNIA 94520 US
CEO: William M. Greenman
Employees: 622
Phone: 19252886000
CERUS CORP / CERS FAQ
Can you describe the business of CERUS CORP?
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 281 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Can you provide the latest stock price for CERUS CORP?
The current stock price of CERS is 2.09 USD. The price increased by 0.97% in the last trading session.
Does CERUS CORP pay dividends?
CERS does not pay a dividend.
What is the ChartMill technical and fundamental rating of CERS stock?
CERS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is CERUS CORP (CERS) stock traded?
CERS stock is listed on the Nasdaq exchange.
How is the valuation of CERUS CORP (CERS) based on its PE ratio?
CERUS CORP (CERS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
Is CERUS CORP (CERS) expected to grow?
The Revenue of CERUS CORP (CERS) is expected to grow by 24.59% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CERS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CERS. When comparing the yearly performance of all stocks, CERS is one of the better performing stocks in the market, outperforming 87.83% of all stocks.
CERS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CERS. CERS may be in some trouble as it scores bad on both profitability and health.
CERS Financial Highlights
Over the last trailing twelve months CERS reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 27.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.42% | ||
| ROE | -25.97% | ||
| Debt/Equity | 0.79 |
CERS Forecast & Estimates
10 analysts have analysed CERS and the average price target is 4.76 USD. This implies a price increase of 127.75% is expected in the next year compared to the current price of 2.09.
For the next year, analysts expect an EPS growth of 25.82% and a revenue growth 24.59% for CERS